论文部分内容阅读
目的研究大环内酯类药物治疗慢性阻塞性肺疾病患者(COPD)稳定期的疗效及其对患者再入院的预防作用。方法抽取2013年7月至2014年8月COPD患者102例,随机法分为干预组和对照组,每组51例,对照组给予常规对症治疗,干预组在此基础上给予大环内酯类药物治疗。比较两组患者的临床疗效,治疗前后1 s用力呼气容积(FEVI)、1 s用力呼气容积占用力肺活量百分比(FEV1/FVC)、75%肺活量最大呼气流量(FEF75%)及6 min行走距离(6 MVT),随访两组患者1年内再入院次数及时间。结果干预组总有效率(90.20%)与对照组(68.63%)比较差异有统计学意义(P<0.05)。干预组治疗后FEV1(2.01±0.83)L、FEV1/FVC(68.16±8.02)%、FEF75%(0.53±0.19)L/S、6 MVT(462.34±16.44)m水平较治疗前显著升高,且高于对照组治疗后,差异均有统计学意义(P<0.05)。干预组1年内再入院次数(2.01±0.49)次及再入院天数(17.58±6.61)d均明显少于对照组,差异有统计学意义(P<0.05)。结论大环内酯类药物用于COPD稳定期患者疗效确切,对预防患者再入院效果显著。
Objective To investigate the efficacy of macrolides in the treatment of patients with chronic obstructive pulmonary disease (COPD) at stable stage and their preventive effects on the admission of patients. Methods Totally 102 patients with COPD from July 2013 to August 2014 were randomly divided into intervention group and control group, with 51 cases in each group. The control group was given conventional symptomatic treatment. The intervention group was given macrolides medical treatement. The clinical efficacy, FEV1 FEV1 / FVC, 75% FEF 75% and FEV 1 FEV of 1 s and 6 min before and after treatment were compared between the two groups. Walking distance (6 MVT), follow-up two groups of patients within a year of re-admission times and time. Results The total effective rate (90.20%) in the intervention group was significantly lower than that in the control group (68.63%) (P <0.05). The FEV1 (68.16 ± 8.02)%, FEF75% (0.53 ± 0.19) L / S and 6 MVT (462.34 ± 16.44) m in FEV1 group were significantly higher than those before treatment Higher than the control group after treatment, the difference was statistically significant (P <0.05). In the intervention group, the number of re-admission (2.01 ± 0.49) and the number of re-admission days (17.58 ± 6.61) d within 1 year were significantly less than those in the control group (P <0.05). Conclusions Macrolide drugs are effective in patients with stable COPD and have a significant effect in preventing re-admission of patients.